Colgate-Palmolive recently announced the authorization of a $5 billion share repurchase program, reflecting the company's effort to increase shareholder value. This development coincided with improved market sentiment, with the S&P 500 potentially breaking a four-week losing spell. Despite broader economic uncertainty highlighted by the Federal Reserve's steady interest rates, Colgate-Palmolive's stock rose 4.5% last month. This positive movement aligns with a general market upturn where all sectors gained ground, and the market rose 2.8% in the last week alone. These circumstances provide insight into the factors behind the company's recent share price increase.

Buy, Hold or Sell Colgate-Palmolive? View our complete analysis and fair value estimate and you decide.

Trump has pledged to "unleash" American oil and gas and these 20 US stocks have developments that are poised to benefit.

Colgate-Palmolive’s shares have achieved a 59.01% total return over the last five years, showcasing a robust performance that reflects the company's sustained efforts in key strategic areas. In this period, the company capitalized on the rising demand for innovative products with initiatives like the launch of the Colgate Total Active Prevention System. Additionally, notable buyback transactions, such as the authorization to repurchase up to $5 billion worth of shares, reinforced investor confidence and potentially supported share price stability.

In 2024, Colgate-Palmolive experienced healthy earnings growth, with full-year net income escalating to US$2.89 billion from US$2.3 billion, and earnings per share seeing corresponding gains. Despite these accomplishments, Colgate-Palmolive faced challenges over the past year, underperforming both the US market and the Household Products industry. Amid currency headwinds and market pressures, the company's proactive focus on enhancing product lines and maintaining a reliable dividend policy has played a fundamental role in driving its long-term shareholder returns.

Understand Colgate-Palmolive's earnings outlook by examining our growth report.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:CL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com